GlassScriptPhysician profile
Robert O Oberman
NPI 1003376765
$2,177.96
in general payments reported to CMS, 2019-2025
13 companies · $541 in 2025
The $541 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $215 · 2023: $680 · 2024: $742 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,963.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,963.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $536.50 | 2022-2024 | Xarelto |
| Alexion Pharmaceuticals, INC. | $480.36 | 2022-2024 | Ultomiris, Soliris |
| Pfizer INC. | $424.26 | 2022-2025 | |
| Abbvie INC. | $271.66 | 2024-2025 | |
| Gilead Sciences, INC. | $157.73 | 2022-2025 | Veklury |
| Inari Medical, INC. | $127.28 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $47.88 | 2024 | Rybelsus, Ozempic |
| Melinta Therapeutics, LLC | $44.14 | 2025 | Rezzayo, Kimyrsa, Orbactiv |
| Bayer Healthcare Pharmaceuticals INC. | $22.29 | 2025 | |
| Chiesi USA, INC. | $21.71 | 2023 | Cleviprex |
| Astrazeneca Pharmaceuticals LP | $15.74 | 2022 | |
| Amgen INC. | $15.61 | 2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $12.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Oberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.